Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss

Cisplatin-based chemotherapy causes hearing loss in 40–60 % of all patients, yet effective preventative options remain limited. Building on prior animal studies, we demonstrate that oral administration of AZD5438, a potent and selective CDK2 inhibitor, provides dose-dependent protection against hear...

Cijeli opis

Bibliografski detalji

Glavni autori:	Yunlong Huang, Xintian Zhang, Enrick Vesanes, Tal Teitz, Jian Zuo
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-01-01
Serija:	Neoplasia: An International Journal for Oncology Research
Teme:	AZD5438 Cisplatin Hearing loss Cancer Cyclin-dependent kinases Pharmacokinetics
Online pristup:	http://www.sciencedirect.com/science/article/pii/S1476558625001307
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!